GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeartSciences Inc (NAS:HSCS) » Definitions » Net Current Asset Value

HSCS (HeartSciences) Net Current Asset Value : $-0.28 (As of Jan. 2025)


View and export this data going back to 2022. Start your Free Trial

What is HeartSciences Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

HeartSciences's net current asset value per share for the quarter that ended in Jan. 2025 was $-0.28.

The historical rank and industry rank for HeartSciences's Net Current Asset Value or its related term are showing as below:

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of HeartSciences was 45.70. The lowest was 0.91. And the median was 1.46.

HSCS's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 5.005
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

HeartSciences Net Current Asset Value Historical Data

The historical data trend for HeartSciences's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartSciences Net Current Asset Value Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24
Net Current Asset Value
-1.26 -27.15 -76.72 -3.56 7.63

HeartSciences Quarterly Data
Apr20 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.26 7.63 4.21 2.03 -0.28

Competitive Comparison of HeartSciences's Net Current Asset Value

For the Medical Devices subindustry, HeartSciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeartSciences's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeartSciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where HeartSciences's Price-to-Net-Current-Asset-Value falls into.


;
;

HeartSciences Net Current Asset Value Calculation

HeartSciences's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Apr. 2024 is calculated as

Net Current Asset Value Per Share(A: Apr. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(7.354-2.186-0-0)/0.677
=7.63

HeartSciences's Net Current Asset Value (NCAV) per share for the quarter that ended in Jan. 2025 is calculated as

Net Current Asset Value Per Share(Q: Jan. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(3.629-3.917-0-0)/1.032
=-0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeartSciences  (NAS:HSCS) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


HeartSciences Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of HeartSciences's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartSciences Business Description

Traded in Other Exchanges
N/A
Address
550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Executives
David R. Wells director 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent director 750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz director, officer: See Remarks 3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson director, officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092